2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2807 Body composition and outcomes after B-cell maturation antigen (BCMA)- directed chimeric antigen receptor T-cell (CAR-T) therapy for multiple myeloma (MM)

Malvika Gupta, MD, Katharine Dooley, MPH2, Gian Marco Conte, MD, PhD3, Joselle M Cook, M.D.4, Francis Baffour, MD5, Shannon Strader, DO, MS6, Andre De Menezes Silva Corraes, MD7, Christoph Schaefers, MD8, Melinda Tan, MD9, Saurabh Zanwar, MBBS, MD10, Moritz Binder, MD, MPH11, Taxiarchis Kourelis, MD12, Rahma Warsame, MD13, Wilson Gonsalves, MD14, Morie Gertz, MD15, Prashant Kapoor, MD16, Shaji Kumar, MD17, Yi Lin Jr, MD, PhD18, Nadine Abdallah I, MD19
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States

Background: Outcomes following BCMA-directed CAR-T therapy for MM are heterogeneous. Current risk stratification relies on disease- & laboratory-related parameters & does not account for patients’ physiologic reserve. Body composition metrics derived from standard-of-care (SOC) imaging may provide objective measures of host vulnerability beyond conventional clinical variables. In addition, treatment-related inflammation after CAR-T may contribute to adverse changes in body composition. The prognostic significance of baseline body composition & early post-treatment changes following BCMA-directed CAR-T therapy in MM remain poorly characterized.

Methods: We conducted a retrospective study evaluating patients (pts) with MM who received BCMA-directed CAR-T therapy between 01/2018 & 06/2023 at Mayo Clinic (Rochester, MN). Baseline body composition was quantified from pre-CAR-T PET/CT scans at the L3 vertebral level, including skeletal muscle, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), & total adipose tissue (TAT). Skeletal muscle index (SMI) was calculated from muscle area normalized to height squared, & sarcopenia was defined using validated sex-specific cutoffs for SMI: ≤38.5 cm²/m² for women & ≤52.4 cm²/m² for men (Prado, 2008). Baseline characteristics distribution by sarcopenia status were compared using Wilcoxon rank sum & Fisher’s exact tests. Logistic regression, adjusted for age & ECOG status, was used to evaluate associations between sarcopenia & CAR-T toxicities, including cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, infections, & healthcare utilization. Gray’s test & adjusted cause-specific Cox models were used to compare the cumulative incidence of non-relapse mortality (NRM) by baseline sarcopenia. Cox regression evaluated associations between baseline body composition & progression-free survival (PFS) & overall survival (OS), adjusting for age, sex, ECOG, high-risk FISH, extramedullary disease, & CAR-T product. A landmark analysis assessed the impact of percent change in body composition at one month on OS & PFS using the same adjustment variables.

Results: A total of 107 pts were included. Median age was 65 yrs (IQR 58-72), 41% were female, & >90% were non-Hispanic White; 58 pts received ide-cel, 37 cilta-cel, & 12 on clinical trial. At baseline, 60 pts (56%) had sarcopenia. Pts with sarcopenia were older vs those without sarcopenia (median age, 67 vs 63 years; p=0.048), but disease characteristics, baseline labs, & CAR-T product distribution were similar between groups. Baseline sarcopenia was not associated with major CAR-T toxicities. While the unadjusted incidence of NRM was higher among sarcopenic pts (2-year NRM incidence: 13%, 95% CI = 6%-23% vs. 0% in non-sarcopenic pts, 95% CI = not estimable; p=0.02), this association was no longer statistically significant following adjustment for age & ECOG performance status (cause-specific adjusted HR (aHR), 8.0; 95% CI, 0.97–65.8; p=0.054). Conversely, greater TAT cross-sectional area was independently associated with improved OS (aHR per 50-cm² increase, 0.90; 95% CI, 0.81–0.99; p=0.040) & PFS (aHR, 0.92; 95% CI, 0.84–0.99; p=0.034). Baseline sarcopenia & SMI were not associated with PFS or OS in unadjusted or adjusted analyses.

Early body composition changes after CAR-T therapy were common: 17% experienced >10% loss in SMI by 1 month, while ≥10% loss in TAT, SAT, & VAT occurred in 27%, 23%, & 40% of pts, respectively. A one month landmark analysis including event-free pts with repeat imaging (96 for OS, 92 for PFS) showed that changes in SMI by 1 month were not associated with subsequent PFS or OS. However, loss of adipose tissue was associated with increased risk of death, with higher mortality risk per 10% loss in SAT (aHR, 1.35; 95% CI, 1.01–1.80; p=0.044), VAT (aHR, 1.28; 95% CI, 1.00–1.63; p=0.047), & TAT (aHR, 1.44; 95% CI, 1.05–1.97; p=0.024); this association was not observed with PFS.

Conclusion: In this cohort of pts with MM undergoing BCMA-directed CAR-T therapy, greater baseline adiposity & preservation of adipose tissue after treatment were associated with improved survival. Baseline sarcopenia was common but not associated with PFS or OS. Body composition analysis using SOC imaging may provide prognostic & actionable information for pts receiving CAR-T therapy. These data may also help identify high-risk pts who could benefit from targeted supportive care or nutritional interventions.
Malvika Gupta, MD: No relevant conflicts of interest to declare.